| Hemogenic and non-hemogenic endothelium can be distinguished by the activity of fetal liver kinase (Flk)-1 promoter/enhancer during mouse embryogenesis. | | Hirai, H., Ogawa, M., Suzuki, N., Yamamoto, M., Breier, G., Mazda, O., Imanishi, J. and Nishikawa, S-I. | Blood 101, 886-893 (2003) | | |
| | | |
| Aberrant iron accumulation and oxidized status of erythroid-specific d-aminolevulinate synthase (ALAS2)-deficient definitive erythroblasts. | | Harigae, H., Nakajima, O., Suwabe, N., Yokoyama, H., Furuyama, K., Sasaki, T., Kaku, M., Yamamoto, M. and Sassa, S. | Blood 101, 1188-1193 (2003) | | |
| | | |
| Functional Analysis of Basic Transcription Element Binding Protein by Gene Targeting Technology. | | Morita M, Kobayashi A, Yamashita T, Shimanuki T, Nakajima O, Takahashi S, Ikegami S, Inokuchi K, Yamashita K, Yamamoto M, Fujii-Kuriyama Y. | Mol. Cell. Biol. 23, 2489-2500 (2003) | | |
| | | |
| Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. | | Kwak, M.K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M. and Kensler, T.W. | J. Biol. Chem. 278, 8135-45 (2003) | | |
| | | |
| Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. | | Itoh, K., Wakabayashi, W., Katoh, Y., Ishii, T., O'Connor, T. and Yamamoto, M. | Genes Cells 8, 379-391 (2003) | | |
| | | |
| HLF (HIF-2a) is a key factor for pathological angiogenesis in proliferative retinopathy. | | Morita, M., Ohneda, O., Yamashita, T., Takahashi, S., Nakajima, O., Kawauchi, S., Ema, M., Shibahara, S., Udono, T., Tomita, K., Tamai, M., Sogawa, K., Yamamoto, M. and Fujii-Kuriyama, Y. | EMBO J. 22, 1134-1146 (2003) | | |
| | | |
| EPR imaging and analysis of reducing activity in oxidative stress-related Nrf2 transcription factor deficient mice. | | Hirayama, A., Yoh, K., Nagase, S., Ueda, A., Itoh, K., Morito, N., Hirayama, K., Takahashi, S., Yamamoto, M. and Koyama, A. | Free Rad. Biol. Med. 34, 1236-1242 (2003) | | |
| | | |
| Gene expression of detoxifying enzymes in AhR and Nrf2 compound null mutant mouse. | | Noda, S., Harada, N., Hida, A., Fujii-Kuriyama, Y., Motohashi, H. and Yamamoto, M. | Biochem. Biophys. Res. Commun. 303, 105-111 (2003) | | |
| | | |
| Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. | | Moriguchi T, Motohashi H, Hosoya T, Nakajima O, Takahashi S, Ohsako S, Aoki Y, Nishimura N, Tohyama C, Fujii-Kuriyama Y, Yamamoto M. | Proc Natl Acad Sci U S A. 100, 5652-5657 (2003) | | |
| | | |
| Regulation of YB-1 gene expression by GATA transcription factors. | | Yokoyama, H., Harigae, H., Takahashi, S-I., Takahashi, S., Furuyama, K., Kaku, M., Yamamoto, M. and Sasaki, T. | Biochem. Biophys. Res. Commun. 303, 140-145 (2003) | | |
| | | |
| Expression and domain-specific function of GATA-2 during differentiation of the hematopoietic precursor cells in midgestation mouse embryos. | | Minegishi, N., Suzuki, N., Yokomizo, T., Xiaoqing, P., Fujimoto, T., Takahashi, S., Hara, T., Nishikawa, S-i. and Yamamoto, M. | Blood 102, 896-905 (2003) | | |
| | | |
| A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. | | Pi, J., Horikuchi, S., Sun, Y., Nikaido, M., Hayashi, T., Yamauchi, H., Itoh, K., Yamamoto, M., Sun, G., Waalkes, M.P., Shimojo, N. and Kumagai, Y. | Free Rad. Biol. Med. 35, 102-113 (2003) | | |
| | | |
| Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Downﾕs syndrome. | | Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M. and Ito, E. | Blood 102, 2960-2968 (2003) | | |
| | | |
| Transgenic overexpression of GATA-3 in T-lymphocytes improves autoimmune glomerulonephritis in BXSB/MpJ-Yaa genetic background mice. | | Yoh, K., Shibuya, K., Morito, N., Nakano, T., Ishizaki, K., Shimohata, H., Nose, M., Izui, S., Shibuya, A., Koyama, A., Engel, J.D., Yamamoto, M. and Takahashi, S. | J. American. Society Nephrol. 14, 2494-502 (2003) | | |
| | | |
| Identification and characterization of two types of erythroid progenitors that express GATA-1 at distinct levels. | | Suzuki, N., Suwabe, N., Ohneda, O., Obara, N., Imagawa, S., Pan, X., Motohashi, H. and Yamamoto, M. | Blood 102, 2575-2583 (2003) | | |
| | | |
| A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. | | Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T, Yamamoto M. | FASEB J. 17, 1742-1744 (2003) | | |
| | | |
| Nrf2 regulates the sensitivity of death receptor signals through by affecting intra-cellular glutathione levels. | | Morito, N., Yoh, K., Itoh, K., Hirayama, A., Koyama, A., Yamamoto, M. and Takahashi, S. | Oncogene 18, 9275-9281 (2003) | | |
| | | |
| Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. | | Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D.R., Harada, T., Engel, J.D. and Yamamoto, M. | Nature Genetics 35, 238-345 (2003) | | |
| | | |
| Expression of the aflatoxin B1-8,9-epoxide-metabolizing murine glutathioneS-transferase A3 subunit is regulated by the Nrf2 transcription factorthrough an antioxidant response element. | | Jowsey, I.R., Jiang, Q., Itoh, K.,Yamamoto, M. and Hayes, J.D. | Mol. Pharmacol. 64, 1018-1028 (2003) | | |
| | | |
| Hematological aspects of a novel 9-aminoanthracycline, amrubicin. | | Obara,N., Imagawa, S., Nakano, Y., Yamamoto, M., Noguchi, T., and Nagasawa, T. | Cancer Sci. 94, 1104-1106 (2003) | | |
| | | |
| X-linked sideroblastic anemia. | | Yamamoto, M. and Harigae, H. | The NORD Guide to Rare Disorders 3rd edition (Lippincott, Williams & Wilkins. Philadelphia), 373-374 (2003) | (invited review) | |
| | | |
|
研究業績 2003 